Furthermore, expression of the TIGIT ligand, CD155 by melanoma cells or APCs and downregulation of CD226, which competes with TIGIT for binding to CD155, are also required for TIGIT-mediated regulation of antimelanoma CD8+ T cells responses (63, 128). The gene discussed is CD8A; the disease is melanoma.